sellWeak
Emil Kuriakose sold $3,640 of TERN
Chief Medical Officer at Terns Pharmaceuticals, Inc.. 853 shares at an average of $4.27, traded Jul 1, 2025, filed Jul 3, 2025.
Warning score
15Value
$3,640
853 shares
Holdings after
52,464
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$4k at market
- 0Share of holdings soldSold 1.6% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001562180-25-005308, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 1, 2025 | SOpen-market sale Common Stock | -853 | $4.27 | $3,640 | 52,464 | Jul 3, 2025 |
Related signals
Other insiders at Terns Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 51Moderate | Terns Pharmaceuticals, Inc. | Andrew Gengos Chief Financial Officer | $39k 10,000 shares | +67% | |
| 52Moderate | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $90k 23,314 shares | +98% | |
| 45Moderate | Terns Pharmaceuticals, Inc. | Andrew Gengos Chief Financial Officer | $57k 15,000 shares | - | |
| 15Weak | TERNsell Terns Pharmaceuticals, Inc. | Emil Kuriakose Chief Medical Officer | $2,366 952 shares | -2% | |
| 33Weak | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $2,606 510 shares | +3% | |
| 31Weak | Terns Pharmaceuticals, Inc. | Melita Sun Jung Chief Business Officer | $11k 2,250 shares | - | |
| 20Weak | TERNsell Terns Pharmaceuticals, Inc. | Emil Kuriakose Chief Medical Officer | $26k 4,481 shares | -8% | |
| 58Moderate | Terns Pharmaceuticals, Inc. | Amy L. Burroughs Chief Executive Officer | $110k 15,450 shares | +423% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.